Quarterly ResultMay 7, 2026, 04:21 PM
Organogenesis Q1 Revenue Down 58% to $36.3M; Net Loss $53.2M
AI Summary
Organogenesis Holdings Inc. reported a challenging first quarter for 2026, with net revenue decreasing by 58% to $36.3 million and net loss widening to $53.2 million. The company also updated its full-year 2026 revenue guidance, now expecting a decline of 45% to 52% compared to 2025, citing a more measured recovery in market-related headwinds. Despite the difficult start, the CEO expressed confidence in driving market share gains in the second half of 2026.
Key Highlights
- Net revenue for Q1 2026 decreased 58% to $36.3 million from $86.7 million in Q1 2025.
- Advanced Wound Care product revenue fell 63% to $29.5 million in Q1 2026.
- Net loss for Q1 2026 was $53.2 million, compared to a net loss of $18.8 million in Q1 2025.
- Adjusted EBITDA loss increased to $48.2 million in Q1 2026 from $12.5 million in Q1 2025.
- Diluted net loss per share was $(0.44) for Q1 2026, compared to $(0.17) for Q1 2025.
- Fiscal Year 2026 net revenue guidance updated to $270.0 million - $310.0 million, a 45%-52% decline.
- Cash, cash equivalents, and restricted cash stood at $92.1 million as of March 31, 2026.